larotrectinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5305 1223403-58-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • larotrectinib
  • vitrakvi
  • LOXO-101
  • ARRY-470
  • larotrectinib sulfate
Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM. One other kinase TNK2 was inhibited at approximately 100-fold higher concentration. TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3.Chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines.
  • Molecular weight: 428.44
  • Formula: C21H22F2N6O2
  • CLOGP: 2.70
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86
  • ALOGS: -3.26
  • ROTB: 3
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
S (Water solubility) 1 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.160 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 9.419 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 26.182 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.699 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 22.500 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 34.940 % High 1
herg hERG pIC50 4.681 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.698 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 32.509 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 20.150 % High 1
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK14,CDK16,CDK19,CDK2,CDK9,CLK2,CLK4,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GAK,GRK2,GSK3B,INSR,IRAK1,IRAK3,IRAK4,ITK,KDR,KIT,LCK,MAP3K10,MAP3K21,MAP3K7,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MARK4,MET,NTRK1,NTRK3,PDK1,PDK2,PDK4,PIK3CD,SIK2,SIK3,SRC,STK33 50
kinase-selectivity-class AXL,BMX,CAMK2D,CSF1R,EGFR,FLT3,IRAK1,JAK1,KIT,LCK,MAP3K21,NTRK1,NTRK3,PDK1,PIK3CD,SIK2,SIK3 17
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 17.378 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 17.418 High 1
mh-clint Mouse hepatocyte intrinsic clearance 28.774 High 1
mppb Mouse plasma protein binding (% unbound) 21.280 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 39.902 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 41.510 % High 1
rat-kpuu-brain Rat brain Kpuu 0.019 % High 1
rh-clint Rat hepatocyte intrinsic clearance 15.740 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 75.420 % High 1
rppb Rat plasma protein binding (% unbound) 26.280 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 534.564 uM High 1

Approvals:

DateAgencyCompanyOrphan
March 23, 2021 PMDA Bayer Yakuhin, Ltd.
Nov. 26, 2018 FDA LOXO ONCOLOGY INC
Sept. 19, 2019 EMA Bayer AG

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuropathy peripheral 46.18 37.13 22 630 179255 110409392
Drug resistance 38.85 37.13 14 638 56360 110532287

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX12 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000193859 Tropomyosin Receptor Kinases Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01EX Other protein kinase inhibitors 21 drugs
avapritinibcabozantinibcapivasertibentrectinibgilteritiniblenvatinibmidostaurinnintedanibpazopanibpexidartinibpralsetinibquizartinib show all 21 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Malignant Neoplasm indication 367651003
NTRK fusion gene-positive advanced or recurrent solid tumors indication 786710002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.36 acidic
pKa2 3.52 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10005783 Oct. 21, 2029 METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10047097 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10774085 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 8865698 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9447104 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9676783 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10005783 Oct. 21, 2029 METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10047097 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10774085 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 8865698 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9447104 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9676783 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 10005783 Oct. 21, 2029 METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 10047097 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 10774085 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 8865698 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 9447104 Oct. 21, 2029 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 9676783 Oct. 21, 2029 METHOD OF TREATING CANCEROUS SOLID TUMORS
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10285993 Nov. 16, 2035 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10813936 Nov. 16, 2035 METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9782414 Nov. 16, 2035 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10285993 Nov. 16, 2035 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 10813936 Nov. 16, 2035 METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 9782414 Nov. 16, 2035 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 9782414 Nov. 16, 2035 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 10045991 April 4, 2037 METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 11191766 April 4, 2037 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 11484535 April 4, 2037 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 11337967 May 16, 2037 TREATMENT OF SOLID TUMORS THAT HAVE A NTRK GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
EQ 100MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 11974998 May 16, 2037 TREATMENT OF SOLID TUMORS CHARACTERIZED BY A GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 11337967 May 16, 2037 TREATMENT OF SOLID TUMORS THAT HAVE A NTRK GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
EQ 25MG BASE VITRAKVI BAYER HLTHCARE N210861 Nov. 26, 2018 RX CAPSULE ORAL 11974998 May 16, 2037 TREATMENT OF SOLID TUMORS CHARACTERIZED BY A GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 11337967 May 16, 2037 TREATMENT OF SOLID TUMORS THAT HAVE A NTRK GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
EQ 20MG BASE/ML VITRAKVI BAYER HEALTHCARE N211710 Nov. 26, 2018 RX SOLUTION ORAL 11974998 May 16, 2037 TREATMENT OF SOLID TUMORS CHARACTERIZED BY A GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
High affinity nerve growth factor receptor Kinase INHIBITOR IC50 8.19 SCIENTIFIC LITERATURE DRUG LABEL
BDNF/NT-3 growth factors receptor Kinase INHIBITOR IC50 8.09 SCIENTIFIC LITERATURE DRUG LABEL
NT-3 growth factor receptor Kinase INHIBITOR IC50 7.98 SCIENTIFIC LITERATURE DRUG LABEL
Activated CDC42 kinase 1 Kinase IC50 6.24 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase IC50 7.63 CHEMBL

External reference:

IDSource
PF9462I9HX UNII
4038034 VANDF
C4524315 UMLSCUI
CHEBI:755964 CHEBI
CHEMBL3889654 ChEMBL_ID
46188928 PUBCHEM_CID
DB14723 DRUGBANK_ID
CHEMBL3989939 ChEMBL_ID
D11137 KEGG_DRUG
10360 INN_ID
C000609083 MESH_SUPPLEMENTAL_RECORD_UI
8909 IUPHAR_LIGAND_ID
1217200005 SNOMEDCT_US
782977003 SNOMEDCT_US
782991009 SNOMEDCT_US
1223405-08-0 SECONDARY_CAS_RN
299174 MMSL
35642 MMSL
d09074 MMSL
017848 NDDF
017849 NDDF
2104548 RXNORM
PF9462I9HX INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 50419-390 CAPSULE 25 mg ORAL NDA 33 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 50419-391 CAPSULE 100 mg ORAL NDA 33 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 50419-392 SOLUTION, CONCENTRATE 20 mg OROPHARYNGEAL NDA 33 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 50419-393 SOLUTION, CONCENTRATE 20 mg OROPHARYNGEAL NDA 33 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 71777-390 CAPSULE 25 mg ORAL NDA 27 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 71777-391 CAPSULE 100 mg ORAL NDA 27 sections
VITRAKVI HUMAN PRESCRIPTION DRUG LABEL 1 71777-392 SOLUTION 20 mg ORAL NDA 27 sections